Eon Labs announced that the US District Court for the Southern District of New York replaced the Temporary Restraining Order it had issued on November 26, 2003 with a preliminary injunction related to the introduction of Eon Labs' Bupropion HCl, ER 100mg tablets until further order of the court. In addition, the court set the amount of the bond GlaxoSmithKline is required to post at $3 million. The bond will be used to compensate Eon for any damages it suffers if the preliminary injunction is determined to have been improperly granted.
Eon Labs is a generic pharmaceutical company specializing in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products.